LMTK2

Across TCGA pan-cancer cohorts, LMTK2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LMTK2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where LMTK2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types LMTK2 is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

LSCC, HNSC, and LUAD are the cancer types where LMTK2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LMTK2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	−0.338	<.001	8	view →
HNSC	Male	II,III,IV	−0.139	.023	4	view →
LUAD	Male	III,IV	−0.192	.011	2	view →
PDAC	All	All	−0.232	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

LMTK2–LSCC

Open the LSCC breakdown →